ASX Health Stocks: Alcidion soars as it helps bring UK patient records into digital age

Alcidion has jumped 23pc after being chosen as preferred supplier in UK for a new Electronic Patient Record system
Memphasys provides positive progress update to investors

Alcidion chosen as preferred supplier in UK

Alcidion Group (ASX:ALC) jumped 23% this morning after announcing that it has been chosen as the preferred supplier for North Cumbria Integrated Care (NCIC) NHS Foundation Trust’s new Electronic Patient Record (EPR) system, following a rigorous competitive tender process.

This selection marks a significant milestone in Alcidion’s relationship with NCIC, expanding upon its existing collaboration where Alcidion’s Patient Administration System (Silverlink PCS) has been instrumental in meeting operational needs.

Located in the north of the UK, NCIC serves approximately half a million people across multiple hospitals and community health facilities.

The Trust is an integral part of the North East and North Cumbria Integrated Care System, collaborating closely with primary care networks and support services.

Alcidion will deploy its comprehensive Miya Precision platform, integrating a suite of solutions including the Silverlink PCS, already operational within the Trust.

This implementation aims to provide clinicians with real-time access to patient records, streamline patient flow, and enhance clinical decision-making processes.

Alcidion Group Managing Director, Kate Quirke, said Alcidion’s solution will enable NCIC to expand its digital capabilities while safeguarding current investments.

“At a time when the healthcare system is under enormous pressure, we see this increased speed to deliver value as a real opportunity for our customers,” said Quirke.

Memphasys gives progress updates

Reproductive and fertility-focused biotech company, Memphasys (ASX:MEM), has updated the market on its product development and clinical trial progress.

Memphasys says it has achieved repeat commercial sales in Japan and witnessed multiple successful live births in both Japan and India.

Securing exclusive distribution agreements for Japan, Canada, and New Zealand through Vitrolife Group subsidiaries were keys to its strategic expansion into key global markets, the company said.

Japan, representing approximately 14.5% of the global IVF market, remains a pivotal focus area for Memphasys despite the current absence of insurance reimbursement for its flagship Felix System.

Meanwhile, progress in the clinical trial of the Felix System has gained momentum throughout the June quarter.

Key trial phases, including the “Swim-up” and Density Gradient Centrifugation (DGC), are advancing steadily, with the trial expected to conclude by the end of the current calendar year.

Following completion, Memphasys plans to promptly analyse results and submit regulatory filings to the Therapeutic Goods Administration (TGA).

Memphasys also says it’s prioritising its Oxidative Stress Measurement System, recognising its potential to revolutionise reproductive health diagnostics by offering unique product differentiation.

The company is currently finalising a study to establish baseline levels and thresholds for oxidative stress, crucial for evaluating reproductive performance.